Document is current
Any future updates will be listed below
-
Authors
Flores, Brittany N. https://orcid.org/0000-0002-5614-6901
Yu, Seungyoon B. https://orcid.org/0000-0002-9910-6029
Cohen, Isaac V. https://orcid.org/0000-0003-1827-2429
Fanok, Melania H.
Luan, Wei
Maciuca, Romeo D.
Sun, Linus D.
Tsai, Richard M.
Vissers, Maurits https://orcid.org/0000-0001-7199-7301
Smits, Lars
Bunte, Tommy M.
Bakardjiev, Anna
Balasundar, Srijana
Calvert, Meredith E. K. https://orcid.org/0000-0003-2893-959X
Chin, Marcus Y.
Dobbins, Sarah K.
Dowdle, William E.
Fang, Meng
Heuberger, Jules A. A. C. https://orcid.org/0000-0001-7202-5088
Ha, Connie L.
Huang, Fen
Miyamoto, Takashi
Osipov, Maksim
Madrid San Martin, Lidia
Saund, Katie https://orcid.org/0000-0002-6214-6713
Tatarakis, David
Vu, Anthony Q.
Xiong, Chenling
Yeo, Gene W. https://orcid.org/0000-0002-0799-6037
Groeneveld, Geert Jan
van den Berg, Leonard H. https://orcid.org/0000-0002-6559-3965
Dhuria, Shyeilla
Estrada, Anthony A. https://orcid.org/0000-0001-7615-5912
Jennings, Danna
Sandmann, Thomas https://orcid.org/0000-0002-6601-8890
Ho, Carole
Scearce-Levie, Kimberly
Yulyaningsih, Ernie
Walker, Adam K. https://orcid.org/0000-0001-7954-5801
Di Paolo, Gilbert https://orcid.org/0000-0003-1032-1265
Kane, Lesley A. https://orcid.org/0000-0001-9631-3471
Troyer, Matthew D. https://orcid.org/0000-0002-0821-7509
Lewcock, Joseph W. https://orcid.org/0000-0003-3012-7881
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 7 August 2025
First Online: 18 August 2025
Competing interests
: SBY, IVC, RDM, RMT, AB, SB, MEKC, MYC, MF, FH, MO, KS, CLH, TM, SD, AAE, DJ, CH, GDP, MDT and JWL are current employees and shareholders of Denali Therapeutics. BNF, MHF, LDS, SKD, WD, CX, and KS-L, EY, and LAK are former employees of Denali Therapeutics. MV, LS, GJG. have appointments at CHDR. LS, GJG have appointments at LUMC. TB and LvB. have appointments at UMCU. LHvdB served in advisory boards for Biogen, Amylyx, Ferrer, Corcept, QurAlis, Cytokinetics, Argenx, VectorY, Zambon paid to institution. LHvdB has participated as principal investigator to clinical trials on ALS sponsored by Biogen, Cytokinetics, Ferrer, Amylyx, Wave Life Sciences, Corcept therapeutics, Sanofi, AB Science, IONIS Pharmaceuticals, Apellis Pharmaceuticals, Alexion Pharmaceuticals, Orphazyme, Orion Pharma and Denali. GWY is a co-founder, member of the Board of Directors, on the SAB, equity holder, and paid consultant for Eclipse BioInnovations. GWY is a visiting professor at the National University of Singapore. GWY’s interests have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. The aforementioned authors declare no other competing financial and non-financial interests. The remaining authors declare no competing interests. DNL343 is an investigational drug that has not been approved by any Health Authority.
